Department of Pediatrics,Northwestern University Feinberg School of Medicine,Chicago, Illinois.
Division of Healthcare Quality Promotion,National Center for Emerging and Zoonotic Infectious Diseases,Centers for Disease Control and Prevention, Atlanta, Georgia.
Infect Control Hosp Epidemiol. 2019 Mar;40(3):276-280. doi: 10.1017/ice.2018.347. Epub 2019 Feb 15.
To characterize healthcare provider diagnostic testing practices for identifying Clostridioides (Clostridium) difficile infection (CDI) and asymptomatic carriage in children.
Electronic survey.
An 11-question survey was sent by e-mail or facsimile to all pediatric infectious diseases (PID) members of the Infectious Diseases Society of America's Emerging Infections Network (EIN).
Among 345 eligible respondents who had ever responded to an EIN survey, 196 (57%) responded; 162 of these (83%) were aware of their institutional policies for CDI testing and management. Also, 159 (98%) respondents knew their institution's C. difficile testing method: 99 (62%) utilize NAAT without toxin testing and 60 (38%) utilize toxin testing, either as a single test or a multistep algorithm. Of 153 respondents, 10 (7%) reported that formed stools were tested for C. difficile at their institution, and 76 of 151 (50%) reported that their institution does not restrict C. difficile testing in infants and young children. The frequency of symptom- and age-based testing restrictions did not vary between institutions utilizing NAAT alone compared to those utilizing toxin testing for C. difficile diagnosis. Of 143 respondents, 26 (16%) permit testing of neonatal intensive care unit patients and 12 of 26 (46%) treat CDI with antibiotics in this patient population.
These data suggest that there are opportunities to improve CDI diagnostic stewardship practices in children, including among hospitals using NAATs alone for CDI diagnosis in children.
描述医疗保健提供者识别艰难梭菌(梭状芽孢杆菌)感染(CDI)和无症状携带的诊断检测实践,以适用于儿童。
电子调查。
通过电子邮件或传真向美国传染病学会新兴感染网络(EIN)的所有儿科传染病(PID)成员发送了一份 11 个问题的调查。
在 345 名符合条件的 EIN 调查应答者中,有 196 名(57%)应答者;其中 162 名(83%)知晓其机构针对 CDI 检测和管理的政策。此外,159 名(98%)应答者知晓其机构的艰难梭菌检测方法:99 名(62%)采用核酸扩增技术(NAAT)而不进行毒素检测,60 名(38%)采用毒素检测,或作为单步检测或多步算法。在 153 名应答者中,有 10 名(7%)报告其机构对成形粪便进行艰难梭菌检测,在 151 名应答者中,有 76 名(50%)报告其机构不对婴儿和幼儿进行艰难梭菌检测。仅采用 NAAT 与同时采用毒素检测用于 CDI 诊断的机构之间,基于症状和年龄的检测限制的频率并无差异。在 143 名应答者中,有 26 名(16%)允许对新生儿重症监护病房患者进行检测,在这一患者群体中,有 12 名(46%)用抗生素治疗 CDI。
这些数据表明,有机会改善儿童 CDI 诊断管理实践,包括在仅采用 NAAT 用于儿童 CDI 诊断的医院中。